Closed · RFA-DK-20-502 · CFDA 93.393;93.847;93.866 · Discretionary
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- July 22, 2020
- Close date
- -
- Expected awards
The verdict
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- Varies
- award range
- Closed
- application status
- 93.393;93.847;93.866
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Limited Competition for the Continuation of t… is closed (last close July 22, 2020). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed July 22, 2020
Instrument
Cooperative Agreement
Description
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the end of DPP, the DPP cohort was enrolled in the DPPOS to determine the long-term effects of the DPP interventions on further diabetes development and microvascular complications. The current funding period is focused on examining the effectiveness of early metformin treatment on the development of cancer and cardiovascular disease. The DPPOS study population has aged, and there is an opportunity to study the heterogeneity in chronic disease development and progression in this well-characterized, diverse study population. The primary purpose of this FOA is to support the DPPOS BRC to maintain follow-up the DPPOS cohort to continue to explore contributors to the development of multiple chronic conditions, including, but not limited to, cognitive impairment, cancer, and diabetes vascular complications, and to evaluate whether the DPP interventions have any preventive effect on the development of these chronic conditions. RFA-DK-20-501 will support continuation of the DPPOS Clinical Centers.
Campus applicant desk · Education
Grants.gov prints only higher-education applicant doors for Limited Competition for the Continuation of t… (Public / state-controlled institutions of higher education). This reads as a campus competition desk, not a civic or commercial open call. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Food and Nutrition · Health (ED;FN;HL). Only 173 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 06
- Public / state-controlled institutions of higher education
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Limited Competition for the Continuation of t… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.847;93.866 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |